[go: up one dir, main page]

DE602005006294D1 - Reinigungsverfahren für bakterielles cytolysin - Google Patents

Reinigungsverfahren für bakterielles cytolysin

Info

Publication number
DE602005006294D1
DE602005006294D1 DE602005006294T DE602005006294T DE602005006294D1 DE 602005006294 D1 DE602005006294 D1 DE 602005006294D1 DE 602005006294 T DE602005006294 T DE 602005006294T DE 602005006294 T DE602005006294 T DE 602005006294T DE 602005006294 D1 DE602005006294 D1 DE 602005006294D1
Authority
DE
Germany
Prior art keywords
bacterial cytolysin
salt
extract
cytolysin
cleaning procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005006294T
Other languages
English (en)
Other versions
DE602005006294T2 (de
Inventor
Ralph L Biemans
Carine Goraj
Emmanuel Mertens
A Vandercammen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of DE602005006294D1 publication Critical patent/DE602005006294D1/de
Application granted granted Critical
Publication of DE602005006294T2 publication Critical patent/DE602005006294T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE602005006294T 2004-09-22 2005-09-20 Reinigungsverfahren für bakterielles cytolysin Expired - Lifetime DE602005006294T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0421083 2004-09-22
GBGB0421083.7A GB0421083D0 (en) 2004-09-22 2004-09-22 Purification process
PCT/EP2005/010258 WO2006032499A1 (en) 2004-09-22 2005-09-20 Purification process for bacterial cytolysin

Publications (2)

Publication Number Publication Date
DE602005006294D1 true DE602005006294D1 (de) 2008-06-05
DE602005006294T2 DE602005006294T2 (de) 2008-08-14

Family

ID=33397075

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005006294T Expired - Lifetime DE602005006294T2 (de) 2004-09-22 2005-09-20 Reinigungsverfahren für bakterielles cytolysin

Country Status (15)

Country Link
US (1) US20070231876A1 (de)
EP (1) EP1791860B1 (de)
JP (1) JP4934591B2 (de)
AT (1) ATE393165T1 (de)
CA (1) CA2580113C (de)
CY (1) CY1107960T1 (de)
DE (1) DE602005006294T2 (de)
DK (1) DK1791860T3 (de)
ES (1) ES2304724T3 (de)
GB (1) GB0421083D0 (de)
HR (1) HRP20080242T3 (de)
PL (1) PL1791860T3 (de)
PT (1) PT1791860E (de)
SI (1) SI1791860T1 (de)
WO (1) WO2006032499A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101052996B1 (ko) 2003-03-13 2011-07-29 글락소스미스클라인 바이오로지칼즈 에스.에이. 박테리아 세포용해소에 대한 정제 공정
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PT1973564T (pt) 2005-12-22 2017-01-24 Glaxosmithkline Biologicals Sa Vacina compreendendo conjugados polissacarídicos capsulares de streptococcus pneumoniae
WO2008014570A2 (en) * 2006-08-03 2008-02-07 The University Of Newcastle Research Associates (Tunra) Limited Treatment and prevention of allergic airways diseases
AU2008267208B2 (en) 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
EP2252326A4 (de) * 2008-02-01 2012-08-29 Newcastle Innovation Ltd Impfstoffzusammensetzungen
MX2012002639A (es) 2009-09-03 2012-03-14 Pfizer Vaccines Llc Vacuna de pcsk9.
US9878029B2 (en) 2011-03-22 2018-01-30 Serum Institute Of India Private Limited Process for preparation of polysaccharides
RU2592686C2 (ru) * 2011-04-22 2016-07-27 ВАЙЕТ ЭлЭлСи Композиции, относящиеся к мутантному токсину clostridium difficile, и способы их применения
CN103533953A (zh) 2011-05-17 2014-01-22 葛兰素史密丝克莱恩生物有限公司 针对肺炎链球菌的疫苗
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3607966A1 (de) 2014-01-21 2020-02-12 Pfizer Inc Immunogene zusammensetzungen mit konjugierten kapselsaccharid-antigenen und verwendungen davon
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
FI3244917T3 (fi) 2015-01-15 2023-05-25 Pfizer Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
GB201603029D0 (en) 2016-02-22 2016-04-06 Glaxosmithkline Biolog Sa Vaccine
EP3493837B1 (de) 2016-08-05 2022-08-31 Sanofi Pasteur, Inc. Polyvalente pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
ES3024474T3 (en) 2016-12-30 2025-06-04 Vaxcyte Inc Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
SI3570879T1 (sl) 2017-01-20 2022-06-30 Pfizer Inc. Imunogenska kompozicija za uporabo v pnevmokoknih cepivih
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
SG11202006387QA (en) 2018-02-05 2020-07-29 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2019215216B2 (en) 2018-02-05 2025-04-17 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2019256218B2 (en) 2018-04-18 2025-10-16 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
GB201807303D0 (en) * 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7551618B2 (ja) 2018-12-12 2024-09-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
MX2022001241A (es) 2019-07-31 2022-04-20 Sanofi Pasteur Inc Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
US20230085173A1 (en) 2020-02-21 2023-03-16 Pfizer Inc. Purification of saccharides
JP2023546446A (ja) 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
EP4346893A2 (de) 2021-05-28 2024-04-10 Pfizer Inc. Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon
PE20240090A1 (es) 2021-05-28 2024-01-16 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
US20250163484A1 (en) 2022-02-25 2025-05-22 Pfizer Inc. Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
AU2023268745A1 (en) 2022-05-11 2024-11-07 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
KR20250107930A (ko) 2022-11-22 2025-07-14 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
CN120513083A (zh) 2022-12-01 2025-08-19 辉瑞大药厂 肺炎链球菌缀合物疫苗制剂
EP4661911A1 (de) 2023-02-10 2025-12-17 Pfizer Inc. Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250169621A (ko) 2023-04-14 2025-12-03 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2005704C (en) * 1988-12-16 2003-02-11 James C. Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
DE4133707A1 (de) * 1991-10-11 1993-04-15 Behringwerke Ag Verfahren zur reinigung von streptolysin o, intaktes streptolysin o erhaeltlich nach diesem verfahren und seine verwendung
US5652125A (en) * 1996-06-10 1997-07-29 Pharmacia S.P.A. Process for preparing daunorubicin
EP0998557A2 (de) * 1997-07-21 2000-05-10 North American Vaccine, Inc. Modifizierte immunogene pneumolysin, deren zusammensetzungen und deren verwendungen als impfung
KR101052996B1 (ko) * 2003-03-13 2011-07-29 글락소스미스클라인 바이오로지칼즈 에스.에이. 박테리아 세포용해소에 대한 정제 공정
JP4578067B2 (ja) * 2003-06-06 2010-11-10 宏 清水 局所医薬組成物

Also Published As

Publication number Publication date
ES2304724T3 (es) 2008-10-16
HRP20080242T3 (en) 2008-09-30
JP4934591B2 (ja) 2012-05-16
PL1791860T3 (pl) 2008-09-30
SI1791860T1 (sl) 2008-08-31
DE602005006294T2 (de) 2008-08-14
CA2580113C (en) 2018-01-16
DK1791860T3 (da) 2008-07-14
US20070231876A1 (en) 2007-10-04
EP1791860B1 (de) 2008-04-23
CY1107960T1 (el) 2013-09-04
ATE393165T1 (de) 2008-05-15
EP1791860A1 (de) 2007-06-06
WO2006032499A1 (en) 2006-03-30
CA2580113A1 (en) 2006-03-30
JP2008513408A (ja) 2008-05-01
GB0421083D0 (en) 2004-10-27
PT1791860E (pt) 2008-05-20

Similar Documents

Publication Publication Date Title
DE602005006294D1 (de) Reinigungsverfahren für bakterielles cytolysin
CR8997A (es) Produccion de polipeptidos
NZ597756A (en) Method for purifying recombinant adamts13 and other proteins and compositions thereof
DK1651758T3 (da) Fremgangsmåde tl fremstilling af L-lysin eller L-threonin ved anvendelse af Escherichia bakterier med svækket æblesyreenzymaktivitet
ATE342962T1 (de) Zusammensetzungen und verfahren für verbesserte zellkultur
MY163480A (en) Sclerostin binding agents
EA201201131A1 (ru) Топическая композиция и способ лечения кожи
IL199550A (en) A method for purifying an antibody comprising a submerged antibody-polyelectrolyte complex
WO2006069610A8 (en) Process for the production of fine chemicals
SG157346A1 (en) Improved purification of collagenases from clostridium histolyticum liquid culture
WO2004090096A3 (en) Methods for neural differentiation of embryonic stem cells using protease passaging techniques
ATE324030T1 (de) Brassica-transformation durch teilchenbeschuss
NZ593239A (en) Fusion Collagenase in which affinity TAG is linked and method for producing the same
DK1620549T3 (da) Fremgangsmåde til fremstilling af biologiske stoffer ved perfusionsdyrkning af suspenderede dyreceller
MXPA02010147A (es) Antagonistas cd40 para uso en el tratamiento de psoriasis y otras condiciones inflamatorias de la piel.
WO2004011637A3 (en) Modified adamts4 molecules and method of use thereof
ATE415470T1 (de) Herstellungsverfahren für iturin a und dessen homologe
WO2007030674A3 (en) Use of nucleases to improve viability and enhance transgene expression in transfected cells
WO2008055671A3 (de) Verfahren zur aufreinigung wenigstens einer nachzuweisenden zielsubstanz
DE602005007476D1 (de) Verfahren zur reinigung von oozysten mittels enzymatischer verdauung von faeces
WO2004015091A3 (en) Preparation of type ii pneumocytes from stem cells
ATE359359T1 (de) Myeloma zellkultur in einem transferrin-freien medium mit niedrigem eisengehalt
WO2008143255A1 (ja) 細胞集団の製造方法
DE602007012053D1 (de) Affinitätspolypeptid zur reinigung von rekombinanten proteinen
FR2778669B1 (fr) Procede d'expression d'un complexe forme d'au moins un produit du complexe majeur d'histocompatibilite et d'un peptide chez un phage, phages et complexes ainsi obtenus et leurs applications

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: VANDERCAMMEN, A., RIXENSART, BE

Inventor name: GORAJ, CARINE, RIXENSART, BE

Inventor name: BIEMANS, RALPH L., RIXENSART, BE

Inventor name: MERTENS, EMMANUEL, RIXENSART, BE

8364 No opposition during term of opposition